THRB and metabolic dysfunction-associated steatohepatitis: The present study was undertaken to mitigate the adverse effects of therapeutic agents for MASLD or MASH and to enhance the accumulation of THR-β agonists in the liver while maintaining the regulatory role of thyroxine on intra-hepatic lipid metabolism.